The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prediction of relapse-free survival in stage III gastric cancer patients treated with postoperative adjuvant chemotherapy: Random survival forest analysis from the START-2 trial.
 
Hiroki Sato
No Relationships to Disclose
 
Wataru Ichikawa
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Guardant Health; Guardant Health; Kyowa Kirin; Lilly; Merck; MSD K.K; Nihonkayaku; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Kazuhiro Yoshida
No Relationships to Disclose
 
Yasuhiro Kodera
Stock and Other Ownership Interests - Abbvie
Honoraria - Bristol Myers Squibb; Chugai Pharma; Daiichi Sankyo; Edwards Lifesciences; Lilly Japan; Miyarisan Pharmaceutical; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Yakult Honsha
Consulting or Advisory Role - Daii Sankyo
Research Funding - abbott Japan (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Yoshihiro Kakeji
Honoraria - Bristol Myers Squibb; Chugai Pharma; Covidien; DAIICHI SANKYO COMPANY, LIMITED; Johnson & Johnson; Lilly; Merck; Merck Sharp and Dohme; Miyarisan pharmaceutical; Nippon Kayaku; Olympus Marketing, Inc.; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Mitsugu Kochi
No Relationships to Disclose
 
Masazumi Takahashi
Honoraria - Bristol-Myers Squibb Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Akinori Takagane
No Relationships to Disclose
 
Kiyoshi Ishigure
No Relationships to Disclose
 
Masahide Kaji
No Relationships to Disclose
 
Narutoshi Nagao
No Relationships to Disclose
 
Makoto Yamada
No Relationships to Disclose
 
Akiharu Ishiyama
No Relationships to Disclose
 
Takanobu Yamada
Honoraria - BMS; Johnson & Johnson/Janssen; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
 
Norimasa Fukushima
No Relationships to Disclose
 
Toshifumi Yamaguchi
No Relationships to Disclose
 
Masahiro Takeuchi
No Relationships to Disclose
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Merck; MSD K.K
Research Funding - Chugai Pharma; Taiho Pharmaceutical
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization
 
Takeshi Sano
Speakers' Bureau - Ono Pharmaceutical